Last updated: May 24, 2026
Suppliers of gadobenate dimeglumine cluster into (1) original-brand manufacturers that supply finished drug product (FDF) and (2) contract manufacturers that produce bulk gadobenate dimeglumine and/or sterilized vials for branded or private-label products. The supplier set is brand- and geography-dependent, since contrast media is marketed through multiple national marketing authorizations with different MAHs (marketing authorization holders) and local distributors.
Which companies supply gadobenate dimeglumine injection (finished drug product)?
Gadobenate dimeglumine is marketed under brands that vary by country. The “supplier” in procurement terms is typically the branded product manufacturer listed on the local label and packaging and the MAH under the local marketing authorization. In practice, buyers should map:
- Labeler/MAH on the carton and vial label
- Local distributor/wholesaler network
- CMOs for manufacturing sites (if disclosed in regulatory dossiers or inspections)
- Supply chain continuity for the exact vial size and concentration
Brand and labeler mapping (procurement-critical)
For gadobenate dimeglumine injection, vendor selection depends on the jurisdiction and the exact commercial presentation (commonly single-dose vials, strength, and pack size). Product labeling in each region determines the “supplier of record” for tenders and hospital purchasing.
Who manufactures the gadobenate dimeglumine active ingredient (bulk) and does it change by supplier?
The active ingredient (gadobenate dimeglumine) is produced as the gadolinium-based chelate salt, then formulated into an aqueous injection for clinical use. Bulk is supplied to downstream formulation and filling operations by:
- The API manufacturer that holds or licenses the synthesis and control strategy
- Formulation/fill-finish operators that buy API and execute final manufacturing and sterile fill
In contrast media, the API supplier and the finished product supplier can be different entities, even when the branded product appears to come from a single “manufacturer” on the outer carton. Buyers typically validate which party supplies:
- API lot release certificates (for traceability)
- Sterility assurance and aseptic processing controls
- Endotoxin and particulates testing
Are there common contract manufacturing organizations (CMOs) for gadolinium contrast agents?
The supply base for gadolinium contrast agents is frequently shared across the class due to:
- Similar aseptic fill-finish requirements for water-based chelates
- Comparable validation approaches for sterility, subvisible particles, and container closure integrity
- Similar analytical release testing packages
However, identifying the exact CMO for gadobenate dimeglumine requires the company-by-company regulatory and label trace for the specific national authorization. Without jurisdiction and product strength/pack, any “named CMO list” risks mixing facilities that do not produce gadobenate dimeglumine in the relevant market.
Which distributors supply gadobenate dimeglumine in hospitals and tenders?
Hospital supply usually runs through:
- National wholesalers and hospital procurement groups
- Tender-specific procurement contracts tied to the local MAH and regional logistics partners
Distributors can change year to year based on availability, contract re-bids, and allocation when supply is constrained. The stable procurement anchor is the MAH and the product dossier holder, not the transient distributor.
How do suppliers differ across US, EU, and other markets?
Supply chains for gadolinium agents are regionally regulated, so the supplier set differs by:
- Marketing authorization holder (MAH) and labeler entity
- Local packaging and distribution requirements
- Import sourcing and cold chain or controlled storage workflows
- Availability schedules linked to manufacturing site capacity
Procurement teams should align on the specific authorized product in the target market, not the molecule alone.
What supplier information is required for procurement due diligence on gadobenate dimeglumine?
For high-volume hospital purchasing and tender qualification, buyers typically need:
- Certificate of Analysis (CoA) scope for each lot (API and finished product tests)
- GMP status and manufacturing site confirmation
- Sterility and endotoxin release documentation
- Shelf-life, storage conditions, and stability protocol summary
- Traceability data (batch-to-batch consistency) for the exact vial configuration
How many suppliers are realistically in the gadobenate dimeglumine supply chain?
Across all markets, the count of viable suppliers is constrained because gadobenate dimeglumine is niche compared with broader gadolinium agents. The realistic procurement universe typically includes:
- A small number of API suppliers
- A limited number of aseptic fill-finish sites able to produce the finished sterile vials under GMP
- Local distributors that vary by country
A molecule-level “supplier list” often overstates competition by aggregating different labels and jurisdictions.
What is the strongest way to identify the correct supplier for a specific gadobenate dimeglumine product?
Use the exact commercial presentation and jurisdiction to lock:
- MAH/labeler on the unit pack
- NDC (US) or national product code (EU and other markets)
- Manufacturing site stated on the packaging or in the local regulatory catalog
- Lot release and CoA manufacturer name and address
- Importer of record for tender bids where applicable
This approach avoids mismatches where the same molecule is manufactured by one entity but sold under another entity’s packaging and marketing authorization.
Key Takeaways
- “Suppliers” for gadobenate dimeglumine depend on the jurisdiction and the exact branded vial presentation.
- The procurement-critical supplier is the labeler/MAH and the manufacturer of record shown on the unit pack and lot-specific CoA, not the molecule-level name alone.
- The supply chain usually splits into API manufacturing and sterile fill-finish, with potential differences between the two.
- Tender qualification should be anchored to batch traceability, GMP manufacturing site confirmation, and lot release documents for the exact vial strength and pack.
FAQs
-
How can I verify the manufacturer of gadobenate dimeglumine for my tender lot?
Use the CoA manufacturer-of-record and the unit pack labeler/MAH tied to the exact product code and strength.
-
Does gadobenate dimeglumine sourcing differ for different vial strengths or pack sizes?
Yes. Labeler, MAH packaging, and potentially fill-finish sites can differ by presentation.
-
What documents do hospitals typically require from gadobenate dimeglumine suppliers?
Lot CoA, GMP site confirmation, sterility/endotoxin release evidence, traceability, and stability/shelf-life documentation.
-
Are API and finished product suppliers always the same for gadobenate dimeglumine?
No. Bulk API suppliers can differ from the sterile fill-finish or finished product manufacturer.
-
Which data points matter most when assessing supplier continuity for gadolinium contrast agents?
Manufacturing site capacity, validated aseptic fill operations, and allocation history tied to the specific authorized product.
References
- FDA. Orange Book. U.S. Food and Drug Administration.
- EMA. European Medicines Agency: Public assessment reports and product information. European Medicines Agency.
- WHO. GMP and quality assurance guidance for pharmaceutical products. World Health Organization.
